Drugs in the Pipeline
Poziotinib Under Review for Previously Treated HER2 Exon 20 Insertion Mutation Positive NSCLC
A PDUFA target date of November 24, 2022 has been set for the application.
Your search for non small cell lung cancer returned 7 results
Drugs in the Pipeline
Adagrasib Under Review for Previously Treated KRAS G12C-Mutated NSCLC
The application is supported by data from the registration-enabling cohort of the phase 2 KRYSTAL-1 study evaluating adagrasib in adults with NSCLC harboring the KRASG12C mutation following prior systemic therapy.
Drugs in the Pipeline
Trastuzumab Deruxtecan Gets Priority Review for Previously Treated HER2-Mutant Metastatic NSCLC
The sBLA is supported by data from the phase 2 DESTINY-Lung01 trial, along with a phase 1 trial published in Cancer Discovery.
Drugs in the Pipeline
FDA Rejects Sintilimab Combo for First-Line Treatment of Nonsquamous NSCLC
Sintilimab is an investigational programmed death receptor-1 (PD-1) inhibitor.
Drugs in the Pipeline
Trial Evaluating Tiragolumab Combo in PD-L1 High NSCLC Misses PFS Endpoint
The phase 3 study compared tiragolumab plus atezolizumab with placebo plus atezolizumab in adults with PD-L1 high locally advanced, unresectable or metastatic NSCLC.
Drugs in the Pipeline
Trial Evaluating Tiragolumab Combo for Extensive-Stage SCLC Misses Endpoint
Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and suppresses the immune response to cancer.
Drugs in the Pipeline
Durvalumab Plus Chemo Granted Priority Review for Biliary Tract Cancer
The sBLA was supported by data from the phase 3 TOPAZ-1 trial.
